Published • loading... • Updated
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
Summary by Carroll County Mirror-Democrat
3 Articles
3 Articles
The Norfolk Daily News+2 Reposted by 2 other sources
ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026
– Updated data across two dose levels of 200 mW/cm and 400 mW/cm in LA-PDAC trial show 71% (5/7) patients resected
Coverage Details
Total News Sources3
Leaning Left0Leaning Right1Center1Last UpdatedBias Distribution50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium
